FDA Grants Fast Track Designation to NUV-422 in High-Grade Gliomas

Article

NUV-422 has demonstrated favorable blood-brain barrier penetration in patients with high-grade gliomas.

The FDA has granted a fast track designation to NUV-422 for the treatment of patients with high-grade gliomas which includes glioblastoma multiforme, according to a press release from the drug’s developer, Nuvation Bio Inc.1

In preclinical phase 1/2 study (NCT04541225), NUV-422, a CDK 2/4/6 inhibitor, has demonstrated favorable blood-brain barrier penetration in a population of patients with recurrent or refractory high-grade gliomas. Additionally, NUV-422 was designed to limit CDK1 inhibition, which is a probable source of toxicity in other second-generation inhibitors.

“We are pleased that NUV-422 received FDA Fast Track designation because it highlights the serious unmet need of patients with brain cancer and the potential of our lead drug candidate NUV-422 to serve as an innovative new treatment option for high-grade gliomas, including glioblastoma multiforme,” David Hung, MD, founder, president, and chief executive officer of Nuvation Bio, said in the press release.

In the trial, NUV-422 is also being examined in several other solid tumors types, including breast and prostate cancer. The non-randomized study has an estimated enrollment of 218 patients. In the phase 1 portion of the study, patients were to receive NUV-422 at escalating dose levels until the maximum tolerated dose was reached. The second phase 2 of the study will administer NUV-422 at the recommended dose.

The primary end points included phase 1 dose escalation with incidence of treatment-emergent adverse effects, serious adverse effects, and dose limiting toxicities. The phase 2 dose expansion cohort included determining an objective response rate and duration of response.

Eligibility criteria for all phase cohorts required that patients must have recovered from toxicity from prior anti-cancer therapy. Other criteria include having adequate bone marrow and organ function, as well as having a life expectancy of more than 3 months.

NUV-422 has previously received an orphan drug designation during in March 2021.2 NUV-422 is currently being studied in hormone receptor–positive, HER2-negative advanced breast cancer, with and without brain metastases, and metastatic castration resistant prostate cancer.

“Enrollment is ongoing in our expanded phase 1/2 monotherapy study of NUV-422 for the treatment of adults with recurrent or refractory high-grade gliomas and solid tumors. We look forward to continuing to work closely with the FDA to expedite the development of NUV-422 with data from the Phase 1 portion of the study, which is on track for 2022,” Hung concluded.

References

1. Nuvation Bio receives FDA fast track designation for NUV-422 for the treatment of high-grade gliomas, including glioblastoma multiforme. News Release. Nuvation Bio Inc. December 15, 2021. Accessed December 15, 2021. https://prn.to/3DZ967h

2. Nuvation Bio granted orphan drug designation for NUV-422 for the treatment of patients with malignant gliomas. News Release. March 11, 2021. Accessed December 15, 2021. https://bit.ly/326ost7

Recent Videos
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Related Content
Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.

Scorpion Venom Approach May Prove “Powerful” in Glioblastoma Research

Russ Conroy
November 13th 2025
Article

Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Interim data from the phase 1b CLOVER-2 trial evaluating iopofosine I 131 in children and adults with high-grade glioma supported the FDA’s decision.

FDA Grants Iopofosine I 131 Rare Pediatric Drug Designation in R/R Glioma

Roman Fabbricatore
October 30th 2025
Article

Interim data from the phase 1b CLOVER-2 trial evaluating iopofosine I 131 in children and adults with high-grade glioma supported the FDA’s decision.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.

Collagen Implant May Improve Local Control of Metastatic Brain Tumors

Russ Conroy
October 23rd 2025
Article

Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.

Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features

Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features

Nanuli Gvazava, MD;Tolga Tuncer, MD;Wei Zhang, MD, PhD;Anup Kasi, MD, MPH;Uma Bhoot
September 17th 2025
Article

A patient case of a 76-year-old man with a rare glioblastoma variant showcased the importance of molecular profiling in diagnosing and guiding treatment for brain tumors.